ARS Pharmaceuticals Q3 revenue rises on higher neffy sales
SPRY•ARS Pharmaceuticals said third-quarter revenue rose year over year, driven by higher U.S. neffy sales. Its net loss narrowed to $35.59 million, and it reaffirmed its path to cash flow breakeven by the end of 2027.
1. Quarterly results
ARS Pharmaceuticals reported higher third-quarter revenue year over year, driven by increased U.S. sales of neffy. The company reported a net loss of $35.59 million, a loss per share of $0.36, and $138.40 million in cash and investments.
2. Expenses and outlook
Operating expenses were $71.88 million. Selling, general and administrative expenses fell 42% from a year earlier after the company discontinued broad consumer advertising and shifted to focused commercial investment. Research and development expenses rose following a $12.5 million payment for exclusive intellectual property rights. ARS reaffirmed its path to cash flow breakeven by the end of 2027 and expects second-half 2026 SG&A and R&D expenses of $114 million to $126 million.
3. Trial plans
ARS expects interim Phase 2b ARS-2 trial data in the first quarter of 2027. The company said market share gains were concentrated in accounts targeted by its field team, where it reached 9%.
